GlaxoSmithkline Pharmaceuticals Ltd. specializes in Pharmaceuticals within the Healthcare sector.
GlaxoSmithkline Pharmaceuticals Ltd., with Security Code 500660, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 9,298.00 | 1,944.80 | 9,596.30 | 11.48 | -1,325.80 | 298.30 | -181.00 | 2,706.20 |
| 2023-10-01 | 2023-12-31 | 8,049.80 | 454.90 | 8,333.20 | 2.69 | -1,321.50 | 283.40 | -171.10 | 651.10 |
| 2023-10-01 | 2023-12-31 | 8,052.60 | 457.20 | 8,333.70 | 2.70 | -1,290.10 | 281.10 | -171.10 | 654.30 |
| 2023-07-01 | 2023-09-30 | 9,533.80 | 2,155.40 | 9,818.50 | 12.72 | -1,715.50 | 284.70 | -181.10 | 2,965.10 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 5% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 17% |
| 3 Years: | 20% |
| 1 Year: | 83% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 6% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 9% |
| 3 Years: | 11% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 17% |
| 3 Years: | 20% |
| 1 Year: | 83% |
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of GSK's Shingrix vaccine for the prevention of shingles (herpes zoster) in adults 50 years and older.
Positive top-line results from the Phase 3 COMET-ICE trial evaluating VIR-2218, an investigational monoclonal antibody for the treatment of COVID-19, have been announced by GSK and Vir Biotechnology, Inc. (Nasdaq: VIR).
GSK and CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative mRNA-based vaccines, today announced a collaboration to develop and commercialize next-generation mRNA vaccines.
